A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Delamanid Approved by European Medicines Agency (EMA)
The EMA advisory panel recommended approval of delamanid (brand name: Deltyba) for treatment of MDR-TB on Thursday, November 21. This represents a reversal of the EMA denial of approval just last July. The EMA attributes its reversal to submission by Otsuka of further safety and efficacy data on use of the drug for 6 months. Details of exactly what the label will say are as yet unclear, but delamanid use is to be recommended “as part of an appropriate combination regimen…for pulmonary MDR-TB”. RESIST-TB is pleased to see that this exciting new drug has now gained its first regulatory approval. We hope that this approval will energize the company to move forward quickly with its plans for expanded access to the drug.
Recent News and Announcements
Parr JB, Mitnick CD, Atwood SS, Chalco K, Bayona J, Becerra MC. Clin Infect Dis. 2013 Oct 28. We estimated the proportion of household contacts whose drug-susceptibility test results matched those of the purported source patient with multidrug-resistant tuberculosis. 99 (88.4%) contacts had isolates resistant to isoniazid and rifampin, and 41 (36.6%) contacts had isolates with results [...]
Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K; for the TB-NEAT team. Lancet. 2013 Oct 25. pii: S0140-6736(13)62073-5. doi: 10.1016/S0140-6736(13)62073-5 BACKGROUND: The Xpert MTB/RIF test for tuberculosis is being rolled out in many [...]
Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. Thorax. 2013 Sep 24. doi: 10.1136/thoraxjnl-2013-203900 BACKGROUND: Few studies have described the management of multidrug-resistant (MDR) tuberculosis (TB) in children and evidence-based guidance on management is lacking. We describe the presentation, treatment and outcome in children treated for severe and non-severe MDR-TB in Cape Town, South Africa. METHODS: [...]
View the Global TB Report here
If you missed our Annual Meeting at the 2013 Union World Conference on Lung Health, check out our presentation for an update on our activities from the last year. Annual Meeting Union Presentation 2013